Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lobucavir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Allowed:
* Aerosolized pentamidine.
* TMP / SMX.
* Isoniazid.
* Dapsone.
* Fluconazole.
* Ketoconazole.
* Rifabutin.
* Fluoxetine HCl.
* Acetaminophen.
* Antacids.
* Metamucil.
* Multivitamins.
* Other drugs with approval from sponsor.
Patients must have:
* AIDS.
* CD4 count \< 200 cells/mm3.
* Cytomegalovirus ( CMV ) viruria and virosemenia.
* No evidence of intraocular CMV.
Exclusion Criteria
Patients with the following symptoms or conditions are excluded:
* Acute or chronic cardiovascular, pulmonary, renal, hepatic, pancreatic, hematologic, endocrine, neurological, or other unstable illness.
* Inability to take oral medication.
* Allergy to nucleoside analogs.
* Diarrheal illness.
* Poor venous access.
* Positive test for drugs of abuse.
* Any other condition that would render patient unsuitable for study.
Patients with the following prior conditions are excluded:
* History of pancreatitis.
* Recent diarrheal illness.
* History of weight loss.
* Acute serious illness within 4 weeks prior to study entry.
Prior Medication:
Excluded within 4 weeks prior to study entry:
* Erythropoietin.
* Any agent with anti-CMV activity.
* Other investigational agents.
Prior Treatment:
Excluded within 4 weeks prior to study entry:
* Surgery.
* Blood transfusion. Drug abuse.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mount Zion Med Ctr / UCSF
San Francisco, California, United States
San Francisco Veterans Adm Med Cntr
San Francisco, California, United States
Univ of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI459-007
Identifier Type: -
Identifier Source: secondary_id
248A
Identifier Type: -
Identifier Source: org_study_id